Product Description
PNC-27 chimeric anticancer peptide (CAS 1159861-00-3) is a high-purity synthetic bioactive peptide specifically designed for oncology research. This product is formed by fusing the HDM-2 binding domain of the human tumor suppressor protein p53 with a transmembrane penetration leader sequence. Its core mechanism involves specifically targeting and binding to the highly expressed HDM-2 protein on the cancer cell membrane, forming transmembrane pores on the tumor cell surface, thereby selectively inducing cancer cell lysis and necrosis. As a p53-independent cell lysis tool, it is widely used in laboratory studies of the in vitro and in vivo mechanisms of various malignant tumors and drug-resistant cell lines, including breast cancer, pancreatic cancer, melanoma, and leukemia.
Product benefits
Highly Selective Tumor Lysis: PNC-27 selectively targets and kills cancer cells by creating transmembrane pores in their cell membranes, leading to rapid cell necrosis without damaging surrounding healthy tissue [1159861-00-3].
Independent of p53 Status: Unlike traditional chemotherapies that require a functional p53 gene to trigger apoptosis, PNC-27 destroys cancer cells purely via cell-membrane pore formation, making it effective against cells with mutated or deleted p53 genes.
Overcomes Multi-Drug Resistance (MDR): Because its physical action relies on membrane-disrupting pore formation rather than metabolic or genetic pathways, cancer cells cannot easily develop defense mechanisms against it.
Dual Action (Internal & External): Beyond splitting open the outer membrane, internalized PNC-27 molecules penetrate deeper to disrupt the cell’s mitochondrial membrane potential, ensuring complete tumor destruction.